What did @nicolegrecopeepas actually say?
This is a clinical consultation clip, not a hype reel, which puts it in a different category than most peptide content. Nicole sits with a physician identified as "Dr. Elisa" and reviews actual lab results. The doctor explains that rising FSH and LH levels signal the ovaries are running low on eggs, that hormone replacement is symptom-driven and individualized, and that Nicole's IGF-1 went from 124 to 140, which the doctor attributes to ipamorelin and tesamorelin. Nicole is also told her testosterone and thyroid panels are normal. No specific doses are named, no miracle outcomes are promised. That restraint matters.
The framing is mostly responsible. The doctor says "sometimes" when discussing who gets started on HRT, and explicitly notes that protocols change every three to four months. Nicole is told to "make good life choices" regarding pregnancy risk, which gets a laugh but is actually medically appropriate advice given her FSH normalized this cycle.
Does the science back this up?
Mostly, yes, on the hormone side. The FSH/LH explanation is textbook perimenopause physiology and is well-supported in the literature. Soules et al. (2001, Menopause) established the STRAW staging system that describes exactly this pattern of rising gonadotropins as ovarian reserve declines. The claim that estradiol and progesterone are "the most commonly replaced" hormones in this population is accurate, consistent with the Menopause Society's 2023 position statement.
The IGF-1 increase is where things get more complicated. A rise from 124 to 140 ng/mL is real and measurable, and growth hormone secretagogues like ipamorelin do stimulate GH release, which drives IGF-1 production. Sigalos and Pastuszak (2018, Sexual Medicine Reviews) confirmed this mechanism in a review of GH secretagogues. However, attributing that specific numerical change to these peptides requires ruling out confounders including diet, sleep, and cycle phase, none of which are addressed in the clip.
What did they get wrong (or right)?
The FSH and LH explanation is accurate but slightly incomplete. The doctor says these hormones "trigger the release of an egg," which is true, but their more important role in this context is stimulating follicular development. The distinction matters for patients trying to understand why they might still ovulate sporadically even with elevated FSH. This is not a dangerous error, but it is an oversimplification.
The IGF-1 attribution is the weakest link here. A 16-point rise in IGF-1 is within normal intra-individual variability. Clemmons (2011, Nature Reviews Endocrinology) noted that IGF-1 can fluctuate 20 to 30 percent based on nutritional status alone. The doctor says "that's actually working" with confidence that the data does not fully support. It might be working. It also might be noise. Presenting it as confirmed efficacy to an audience of nearly 10,000 viewers is a stretch.
What they got right: the emphasis on individualized protocols, quarterly monitoring, and not pushing testosterone on someone who does not need it. That last point is refreshingly honest for this content category.
What should you actually know?
If you are a woman in perimenopause, the FSH and LH explanation here is genuinely useful. These hormones do rise as egg reserves decline, and that rise is one of the markers clinicians use to assess where you are in the transition. The Menopause Society recommends against using FSH alone to diagnose menopause, precisely because of the variability Nicole demonstrates this cycle, but serial measurements add real information.
On peptides: ipamorelin is a synthetic growth hormone secretagogue. It is not FDA-approved for anti-aging or body composition. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. Using either off-label carries regulatory and safety considerations your prescriber should walk you through in detail. IGF-1 monitoring is appropriate when using these compounds, and the fact that this practice does it quarterly is a reasonable safety practice. Chronically elevated IGF-1 has been associated with increased cancer risk in epidemiological studies, including a meta-analysis by Renehan et al. (2004, Lancet).
Do not interpret a single IGF-1 data point as proof a peptide protocol is working. Ask your provider for trending data across multiple draws before drawing conclusions.